Torin 1

Catalog No.S2827

Molecular Weight(MW): 607.62

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

5 Customer Reviews

Huh-7.5 cells were treated with increasing concentration of Torin 1, a known autophagy inducer, and the autophagy response was assessed by measuring LC3II and p62 levels.

Am J Pathol 2014 184(1), 214-29. Torin 1 purchased from Selleck.

Flag-tagged SENP3 was immunoprecipitated from HeLa cells and used for in vitro phosphorylation assay with [32P]ATP with either the mock-treated or Torin1-treated mTOR/Raptor/MLST8 complex. (Upper) The samples then were subjected to SDS-PAGE, followed by autoradiography. mTOR autophosphorylation is indicated by an asterisk. (Lower) Immunopurified SENP3 was monitored by Western blotting with anti-Flag antibody.

Mol Cell Biol 2014 34(24), 4474-84. Torin 1 purchased from Selleck.
Exp Cell Res, 2018, 363(1):84-94. Torin 1 purchased from Selleck.

Representative Western blots showing LC3 in PP242 (PP) or Torin1 (Tor) treated HepG2 cells. HepG2 cells were treated with 10 uM PP242 or 0.1 uM Torin1 for 24 h.

Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.05.047. Torin 1 purchased from Selleck.
Bone marrow derived macrophages were pre-treated with 10nM Torin 1 for 1h prior to LPS treatment (100 ng/ml). TNF-a production was analyzed 24h later.

Lim Hsiu Kim, Lina from National University of Singapore. Torin 1 purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3S[mtkUUN3ME2wMlAxODNyNjFOwG0>	MUXTRW5ITVJ?
OCUB-M	NI\wS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmL6TWM2OD1yLkCwNVk1KM7:TR?=	MX\TRW5ITVJ?
DOHH-2	M4C2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnIU3hKSzVyPUCuNFAzOjVizszN	MXnTRW5ITVJ?
NOS-1	M4L3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3KTWM2OD1yLkCwNlQzKM7:TR?=	MVrTRW5ITVJ?
L-363	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DwR2lEPTB;MD6wNFI5PCEQvF2=	MkPuV2FPT0WU
RL95-2	NHi5TVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknCTWM2OD1yLkCwN\|Ih\|ryP	M3jqV3NCVkeHUh?=
BL-70	M3L2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPpTWM2OD1yLkCwN\|M4KM7:TR?=	NXjCTFcyW0GQR1XS
TGBC1TKB	NH\QT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\kTWM2OD1yLkCwN\|c6KM7:TR?=	MYHTRW5ITVJ?
697	NGHNWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXvTWM2OD1yLkCwOlM1KM7:TR?=	NVzOV45EW0GQR1XS
RPMI-8226	Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1Kxb2lEPTB;MD6wNFY2OSEQvF2=	MnnpV2FPT0WU
BL-41	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPlSVJmUUN3ME2wMlAxPjl4IN88US=>	MWLTRW5ITVJ?
MRK-nu-1	M{XKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwMEC3NFch\|ryP	NY\IVlhtW0GQR1XS
EW-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwMEC3OFkh\|ryP	NI\KfotUSU6JRWK=
EVSA-T	M3\4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrWTWM2OD1yLkCwPFkzKM7:TR?=	NXT6ZYJDW0GQR1XS
HUTU-80	NUW0fZFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPaUVB[UUN3ME2wMlAxQTJ7IN88US=>	NVfwd4V2W0GQR1XS
VA-ES-BJ	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnyT3NbUUN3ME2wMlAxQTh2IN88US=>	MWLTRW5ITVJ?
GCIY	NG\Wc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLNVpJKSzVyPUCuNFExODdizszN	Ml74V2FPT0WU
ES6	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknPTWM2OD1yLkCxNFg{KM7:TR?=	MX;TRW5ITVJ?
NALM-6	M4LYSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMEGxNFIh\|ryP	NEDZT\|FUSU6JRWK=
LB996-RCC	MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHq4[phKSzVyPUCuNFEyOzdizszN	MoLKV2FPT0WU
EW-16	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\xdZVKSzVyPUCuNFEyQTJizszN	NIrHdm1USU6JRWK=
KALS-1	M4\EXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXTTWM2OD1yLkCxNVk5KM7:TR?=	MonsV2FPT0WU
OPM-2	NELiXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\EfoVKSzVyPUCuNFEzQSEQvF2=	MYLTRW5ITVJ?
KU812	MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMEGyPVYh\|ryP	M4PUWnNCVkeHUh?=
A4-Fuk	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYr0T41vUUN3ME2wMlAyOzF7IN88US=>	M1;TNXNCVkeHUh?=
KGN	NXz5bppkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\0bmlEPTB;MD6wNVM2QSEQvF2=	NG\MXoVUSU6JRWK=
KS-1	NW\ufoJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMEGzPVIh\|ryP	Mlj6V2FPT0WU
no-11	NGntfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7VU\|NKSzVyPUCuNFE{QTVizszN	NWTib4FPW0GQR1XS
PSN1	M3Pscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXZRpBnUUN3ME2wMlAyPDB7IN88US=>	NFPRO2hUSU6JRWK=
SK-LMS-1	M{i1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Pkd2lEPTB;MD6wNVQyOyEQvF2=	M1T0S3NCVkeHUh?=
LS-411N	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfHVnJKUUN3ME2wMlAyPDN7IN88US=>	MYPTRW5ITVJ?
HT-144	M2m1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7BTWM2OD1yLkCxOFUyKM7:TR?=	MWDTRW5ITVJ?
ACN	Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzMUZZ5UUN3ME2wMlAyPSEQvF2=	MVfTRW5ITVJ?
RKO	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIe2OmFKSzVyPUCuNFE2OzNizszN	M{H2cXNCVkeHUh?=
CMK	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMEG1OFMh\|ryP	NX\KZ3h2W0GQR1XS
GB-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHi1[ZdKSzVyPUCuNFE2PTNizszN	NWPsS\|BwW0GQR1XS
KE-37	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMEG1O\|Mh\|ryP	NGe0N3lUSU6JRWK=
no-10	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;OSmlEPTB;MD6wNVU5PCEQvF2=	M4TMNHNCVkeHUh?=
MOLT-16	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjHTWM2OD1yLkCxOlIzKM7:TR?=	M2HxcHNCVkeHUh?=
HEL	NYTUTHVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4eyXmlEPTB;MD6wNVY1KM7:TR?=	NVHFflNuW0GQR1XS
NCI-H1355	NUfBTnBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrOc4dyUUN3ME2wMlAyPjR4IN88US=>	NEHP[2NUSU6JRWK=
IST-MEL1	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LOTmlEPTB;MD6wNVc4PCEQvF2=	M4XNSHNCVkeHUh?=
MHH-PREB-1	M4fjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnFT\|JWUUN3ME2wMlAyQDF6IN88US=>	M{XsZnNCVkeHUh?=
ES8	MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnKzTWM2OD1yLkCxPFQ1KM7:TR?=	NVHsTpkxW0GQR1XS
LC-2-ad	NYPxXnBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMEKxN\|ch\|ryP	MoHZV2FPT0WU
LAMA-84	NXLj[FNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPRXo5lUUN3ME2wMlAzOTZ5IN88US=>	NHvqPJNUSU6JRWK=
BV-173	MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMEKyNFMh\|ryP	MXHTRW5ITVJ?
SW872	NGfZZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMEKyOFch\|ryP	Mn:1V2FPT0WU
SK-UT-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMEKyOlEh\|ryP	M{\6dXNCVkeHUh?=
OS-RC-2	M{DsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjpc4VKSzVyPUCuNFI{OjNizszN	NVX4eoRMW0GQR1XS
NCI-H747	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoixTWM2OD1yLkCyN\|Mh\|ryP	MWDTRW5ITVJ?
MZ2-MEL	NVSzeFdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMEKzN\|ch\|ryP	NIjpWGxUSU6JRWK=
TE-11	NXXLO45UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfiTZVKSzVyPUCuNFI{PzJizszN	M4X6UnNCVkeHUh?=
KURAMOCHI	NGq5RpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljiTWM2OD1yLkCyOFE1KM7:TR?=	M1vBWXNCVkeHUh?=
HD-MY-Z	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v5NWlEPTB;MD6wNlQzPiEQvF2=	NXXrXI5nW0GQR1XS
GI-1	NHXSfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4O0XGlEPTB;MD6wNlQ3QSEQvF2=	NX\FR3JiW0GQR1XS
LB1047-RCC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVz4OWVGUUN3ME2wMlAzPDh6IN88US=>	MXfTRW5ITVJ?
TE-12	M{DKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXGb4xKSzVyPUCuNFI2PSEQvF2=	M360bXNCVkeHUh?=
MZ7-mel	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3mzcWlEPTB;MD6wNlYxQSEQvF2=	NYPjTGxUW0GQR1XS
MMAC-SF	Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMEK2N\|Mh\|ryP	NHLoeJhUSU6JRWK=
A101D	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NISxbGZKSzVyPUCuNFI3PSEQvF2=	M1\vOnNCVkeHUh?=
GR-ST	MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrnRpVKSzVyPUCuNFI3PTVizszN	MYTTRW5ITVJ?
MC116	MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTQZYk1UUN3ME2wMlAzPjhizszN	MX3TRW5ITVJ?
Ramos-2G6-4C10	NW\MXoxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjtVWFKSzVyPUCuNFI4PSEQvF2=	MYfTRW5ITVJ?
ATN-1	M3\mSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVH6WIJnUUN3ME2wMlAzPzh7IN88US=>	NG\FTmxUSU6JRWK=
MFH-ino	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTEdWtPUUN3ME2wMlAzQDF{IN88US=>	MUTTRW5ITVJ?
DEL	Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2S2PWlEPTB;MD6wNlgyPSEQvF2=	MXXTRW5ITVJ?
OCI-AML2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY[xOZp{UUN3ME2wMlAzQDdzIN88US=>	NUDLdmNDW0GQR1XS
LXF-289	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMEK4O\|Ih\|ryP	M{W4WnNCVkeHUh?=
IA-LM	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvTS5RKSzVyPUCuNFI6OTdizszN	M2TCT3NCVkeHUh?=
EoL-1-cell	M3e1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXL1UHRbUUN3ME2wMlAzQTl4IN88US=>	NWnUb\|FQW0GQR1XS
OVCAR-4	NIO0OWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvlXFZjUUN3ME2wMlA{ODl2IN88US=>	MX\TRW5ITVJ?
ES1	NYjvd4l1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PLNGlEPTB;MD6wN\|A6PyEQvF2=	NV\LZmU6W0GQR1XS
CESS	NEmyPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLaeJRKSzVyPUCuNFMxQTlizszN	MoG3V2FPT0WU
GAK	M1Xx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMEOxPFYh\|ryP	NXW3[VlIW0GQR1XS
NTERA-S-cl-D1	M1roOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMEOyNlYh\|ryP	M2LsfnNCVkeHUh?=
TE-10	Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwMEOzNVEh\|ryP	NIfPZ\|BUSU6JRWK=
CCRF-CEM	MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnndGlOUUN3ME2wMlA{OzdzIN88US=>	M{TWenNCVkeHUh?=
NMC-G1	NUGwdlR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMEO0OFgh\|ryP	M13hUHNCVkeHUh?=
HOP-62	MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYmwSVZQUUN3ME2wMlA{PTV4IN88US=>	MU\TRW5ITVJ?
SH-4	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\jTWM2OD1yLkCzOVgzKM7:TR?=	NYTPRpU5W0GQR1XS
NCI-H1648	NXT1UJRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMEO2NlIh\|ryP	Ml7MV2FPT0WU
EB-3	M{nHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMEO2OFMh\|ryP	NE\FcnVUSU6JRWK=
BB65-RCC	NWflXoJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPlTWM2OD1yLkCzOlkyKM7:TR?=	M3:zPHNCVkeHUh?=
BE-13	M3TOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nUSmlEPTB;MD6wN\|c2QSEQvF2=	Mli4V2FPT0WU
CP67-MEL	M{XSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmH0TWM2OD1yLkCzO\|U6KM7:TR?=	NEj5RmxUSU6JRWK=
SW954	M{XBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jVRWlEPTB;MD6wN\|c6KM7:TR?=	M4fwWXNCVkeHUh?=
TE-5	Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMEO4OVQh\|ryP	NHvKU2dUSU6JRWK=
HCE-4	NW[5THdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMEO4OVUh\|ryP	M{jLRnNCVkeHUh?=
LC-1F	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;Yb2lEPTB;MD6wN\|k5QSEQvF2=	MUTTRW5ITVJ?
TK10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXXSoZxUUN3ME2wMlA1ODF7IN88US=>	MlfmV2FPT0WU
SJSA-1	M3nWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFP2[mJKSzVyPUCuNFQyQDhizszN	MVzTRW5ITVJ?
Daudi	MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHH5VnZKSzVyPUCuNFQzOjVizszN	NGTwS2NUSU6JRWK=
SW982	NUDReVhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nXWGlEPTB;MD6wOFI1PiEQvF2=	NU\Kb3pkW0GQR1XS
SF126	NUjmbZV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMESzOlEh\|ryP	NHPIbXpUSU6JRWK=
TE-15	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHOfndKSzVyPUCuNFQ1OzVizszN	MYTTRW5ITVJ?
COLO-684	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUP3bpdMUUN3ME2wMlA1PTZzIN88US=>	NYDlbIxEW0GQR1XS
8-MG-BA	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVG3fGFuUUN3ME2wMlA1PjJ7IN88US=>	MoXUV2FPT0WU
NB13	NILSPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33OdGlEPTB;MD6wOFc4PiEQvF2=	NGjHc5JUSU6JRWK=
HCC1599	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMES4O\|kh\|ryP	M1rUZnNCVkeHUh?=
SK-PN-DW	NH[xTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DkcGlEPTB;MD6wOFk1QSEQvF2=	MXXTRW5ITVJ?
ALL-PO	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkftTWM2OD1yLkC0PVU3KM7:TR?=	NF34Vo9USU6JRWK=
NB6	M{Lkcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHXTWM2OD1yLkC1NlcyKM7:TR?=	NXnpe5BYW0GQR1XS
IST-SL2	NXHXeIt1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DzbWlEPTB;MD6wOVM3OiEQvF2=	NIX0OpJUSU6JRWK=
BB30-HNC	NG\UVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHyW4ZYUUN3ME2wMlA2PzNizszN	M1e2O3NCVkeHUh?=
SW962	NGH0S4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLPTWM2OD1yLkC1O\|Y{KM7:TR?=	MYHTRW5ITVJ?
TGBC24TKB	NVLVXFhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PPcmlEPTB;MD6wOVc6QSEQvF2=	MVPTRW5ITVJ?
KINGS-1	NUf5dWdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;VTWM2OD1yLkC1PFA{KM7:TR?=	M3;HdnNCVkeHUh?=
HC-1	MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXiWZBKSzVyPUCuNFU5OjdizszN	MXTTRW5ITVJ?
RS4-11	Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\uTWM2OD1yLkC1PVM5KM7:TR?=	MnHKV2FPT0WU
LS-123	Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfGTWM2OD1yLkC1PVQzKM7:TR?=	NX6yOVVqW0GQR1XS
A3-KAW	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmK0TWM2OD1yLkC2NlI2KM7:TR?=	NFrOS5dUSU6JRWK=
SNB75	NWP5VoV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1P5[2lEPTB;MD6wOlM1OSEQvF2=	MVfTRW5ITVJ?
SR	MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\GdWlEPTB;MD6wOlM4PCEQvF2=	M2foU3NCVkeHUh?=
LOUCY	M4LLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPJTWM2OD1yLkC2N\|k1KM7:TR?=	MnG5V2FPT0WU
K5	Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwME[0NFMh\|ryP	M2THb3NCVkeHUh?=
Becker	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPRTWM2OD1yLkC2OFIh\|ryP	MWTTRW5ITVJ?
CTV-1	NUTmR4lOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPCTWM2OD1yLkC2OVQ5KM7:TR?=	MUnTRW5ITVJ?
KLE	M1Xxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLLbHZKSzVyPUCuNFY2QDRizszN	MUjTRW5ITVJ?
MZ1-PC	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPYTWM2OD1yLkC2OVk5KM7:TR?=	MXTTRW5ITVJ?
MOLT-4	M4nqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPWZmZ1UUN3ME2wMlA3PjB3IN88US=>	NHTxSG9USU6JRWK=
MLMA	MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwME[3PEDPxE1?	M{nPUHNCVkeHUh?=
A388	NEe4PYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwME[4PVMh\|ryP	NWn2cGtyW0GQR1XS
MV-4-11	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\ZfpBUUUN3ME2wMlA3QTl3IN88US=>	MVPTRW5ITVJ?
DSH1	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHrRZpKSzVyPUCuNFcyPzNizszN	MXTTRW5ITVJ?
MONO-MAC-6	Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPmZoZtUUN3ME2wMlA4OjF{IN88US=>	MlvjV2FPT0WU
ARH-77	Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYj0bI03UUN3ME2wMlA4Ojd6IN88US=>	M37k[XNCVkeHUh?=
LB771-HNC	NYjkUIlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzCdm5KSzVyPUCuNFc2PDlizszN	NXLhd49sW0GQR1XS
PF-382	NIHpRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFr3[JNKSzVyPUCuNFc2PjlizszN	MVLTRW5ITVJ?
KM12	NGTi[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwMEe2OEDPxE1?	NEfzXnJUSU6JRWK=
HAL-01	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEntNVRKSzVyPUCuNFc3PThizszN	M1;nNHNCVkeHUh?=
RPMI-8402	NXrMWHZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\pTWM2OD1yLkC3O\|g6KM7:TR?=	MnTNV2FPT0WU
OMC-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLqTWM2OD1yLkC3PFA1KM7:TR?=	NYTtVVU3W0GQR1XS
HT	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrxTY9KSzVyPUCuNFgh\|ryP	NEPtWGJUSU6JRWK=
QIMR-WIL	NVrPW\|ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMEiwOVUh\|ryP	Mk\RV2FPT0WU
KNS-42	MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1n5dWlEPTB;MD6wPFIxOyEQvF2=	M4jYe3NCVkeHUh?=
BC-3	NETTNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX32SG5xUUN3ME2wMlA5OjB2IN88US=>	MknDV2FPT0WU
ES4	M3z0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnSfo9KSzVyPUCuNFgzQTZizszN	NGTGOW9USU6JRWK=
NCI-H23	MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMEi0OEDPxE1?	MWLTRW5ITVJ?
LB2518-MEL	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfUdY5SUUN3ME2wMlA5Pjl4IN88US=>	M{LrV3NCVkeHUh?=
LC4-1	M3\ObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fX[2lEPTB;MD6wPFc{QCEQvF2=	MnrUV2FPT0WU
SIG-M5	NFjoOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnqdXFKSzVyPUCuNFg6ODRizszN	MWXTRW5ITVJ?
LP-1	M33lcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XuN2lEPTB;MD6wPFk{QCEQvF2=	M{\mfXNCVkeHUh?=
TE-8	NXr0S\|h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;kTWM2OD1yLkC5NFE3KM7:TR?=	M4PoOnNCVkeHUh?=
K-562	NGDtfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPuN\|RvUUN3ME2wMlA6OTJizszN	NEOx[nlUSU6JRWK=
J-RT3-T3-5	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;1UpA2UUN3ME2wMlA6OTV\|IN88US=>	MXHTRW5ITVJ?
DU-4475	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1ryW2lEPTB;MD6wPVE3PSEQvF2=	NIC4WFNUSU6JRWK=
RXF393	NHGzbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwMEm0OlIh\|ryP	NVjw[JpNW0GQR1XS
NB5	NWnMWWFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\jO4ZtUUN3ME2wMlA6PjJ3IN88US=>	NGDKU2NUSU6JRWK=
A704	M1i4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFP5c29KSzVyPUCuNFk4PDFizszN	NETCV\|dUSU6JRWK=
SF268	MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMEm4NlUh\|ryP	M1TCd3NCVkeHUh?=
UACC-257	NFXSdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TGNWlEPTB;MD6wPVg{OyEQvF2=	MWTTRW5ITVJ?
L-428	Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnyTWM2OD1yLkGwN\|Ih\|ryP	M1HBVHNCVkeHUh?=
ST486	NEHRfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DOWGlEPTB;MD6xNFYxPiEQvF2=	NHjZNldUSU6JRWK=
SK-MM-2	M{LGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fNPGlEPTB;MD6xNFcxQSEQvF2=	NV[2WFFnW0GQR1XS
COR-L279	M{X4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDTcZpKSzVyPUCuNVA5OzJizszN	M2r6V3NCVkeHUh?=
JiyoyeP-2003	M2XESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn60TWM2OD1yLkGwPFQ{KM7:TR?=	NX35RWJGW0GQR1XS
GT3TKB	MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13HUWlEPTB;MD6xNFkyQCEQvF2=	MlLrV2FPT0WU
HCE-T	M4ribGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMUC5OEDPxE1?	NIX5SHJUSU6JRWK=
SBC-1	NYftV285T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PRfmlEPTB;MD6xNVEyQSEQvF2=	NF;DdXNUSU6JRWK=
KNS-81-FD	MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjVR\|JKSzVyPUCuNVEzPzNizszN	NGHHXYJUSU6JRWK=
NCI-H2126	M3eyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\aZ3dLUUN3ME2wMlEyOzl2IN88US=>	M1;YdnNCVkeHUh?=
EM-2	NGXkOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\qTWM2OD1yLkGxOVI6KM7:TR?=	NV[yZ2VQW0GQR1XS
JAR	M1[0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMUG1PVgh\|ryP	M2O1eHNCVkeHUh?=
NB17	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnGUoJVUUN3ME2wMlEyPjV{IN88US=>	Ml\GV2FPT0WU
LB647-SCLC	NWrFRVZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMUG3NFUh\|ryP	MYrTRW5ITVJ?
CAL-148	NW\aN2VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4f5UWlEPTB;MD6xNVgh\|ryP	M2XM[XNCVkeHUh?=
K052	Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETHTVFKSzVyPUCuNVE5PTFizszN	MljJV2FPT0WU
KARPAS-299	NX3HcJZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vhS2lEPTB;MD6xNlI{OyEQvF2=	NIOxUXpUSU6JRWK=
KARPAS-422	MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rCO2lEPTB;MD6xNlQ{OiEQvF2=	MkLBV2FPT0WU
LOXIMVI	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHIS5ZkUUN3ME2wMlEzPTF3IN88US=>	MoqyV2FPT0WU
SCC-3	NWLNS3ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\EVGlKSzVyPUCuNVI5PTFizszN	M4LafXNCVkeHUh?=
LU-139	NFnNfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33ZZmlEPTB;MD6xNlk4PSEQvF2=	MorGV2FPT0WU
COLO-320-HSR	M2PrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjRcpV2UUN3ME2wMlE{ODh4IN88US=>	MnrSV2FPT0WU
ONS-76	M1;Pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwMUOxN{DPxE1?	MmnWV2FPT0WU
U-266	NH;RTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMUOyOFUh\|ryP	MlzvV2FPT0WU
HH	NUTKRXVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvDenJ6UUN3ME2wMlE{PTN3IN88US=>	Ml31V2FPT0WU
BB49-HNC	NWf5NFFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfCTWM2OD1yLkGzOVg4KM7:TR?=	MorOV2FPT0WU
NCI-SNU-5	MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDVfVhKSzVyPUCuNVM2QTZizszN	Mnr0V2FPT0WU
C2BBe1	NXvEemkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXOTWM2OD1yLkGzO\|Q3KM7:TR?=	NVrNfmJCW0GQR1XS
ML-2	NXnIT2dGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHk[HdKSzVyPUCuNVM6PTNizszN	MlvWV2FPT0WU
SCH	NF\mXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfxOJQ5UUN3ME2wMlE{QTd2IN88US=>	MWfTRW5ITVJ?
NCI-H82	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEWxPWFKSzVyPUCuNVQyODRizszN	MWrTRW5ITVJ?
MDA-MB-134-VI	MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUmxeIdpUUN3ME2wMlE1OjV{IN88US=>	Mon5V2FPT0WU
SK-N-DZ	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMUS3NVkh\|ryP	M4XMbHNCVkeHUh?=
HL-60	NXjwTIJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMUS5NkDPxE1?	MYTTRW5ITVJ?
LB373-MEL-D	M4DOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwMUW1N\|kh\|ryP	NH\Cb4tUSU6JRWK=
LB831-BLC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMU[wO\|Yh\|ryP	M3TGZnNCVkeHUh?=
SK-NEP-1	NGfQeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMU[xNFEh\|ryP	M{DTT3NCVkeHUh?=
IMR-5	M2XF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\iTWM2OD1yLkG2OFg{KM7:TR?=	NUDM[49vW0GQR1XS
Calu-6	M4n2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXtXG9KSzVyPUCuNVY2OzdizszN	MmfCV2FPT0WU
NCI-H1882	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLtNW83UUN3ME2wMlE3PzJ6IN88US=>	M2jWSXNCVkeHUh?=
NCI-H446	NULhZXNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwMU[4PVEh\|ryP	M{nNNHNCVkeHUh?=
GI-ME-N	NYTKWGtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vIZmlEPTB;MD6xPFAzKM7:TR?=	MnzjV2FPT0WU
MPP-89	NXjyVow6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnhToJbUUN3ME2wMlE5OTJzIN88US=>	NH\Vd3FUSU6JRWK=
CGTH-W-1	NYG2OpROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVq3[mg{UUN3ME2wMlE5PDN4IN88US=>	NFfwc4FUSU6JRWK=
MEG-01	M2D2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\KTWM2OD1yLkG4OlI5KM7:TR?=	M4HpNHNCVkeHUh?=
NCI-H748	NHm5ZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LkdmlEPTB;MD6xPFkyOSEQvF2=	MWnTRW5ITVJ?
COLO-829	NUX0W3VCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXqPZlkUUN3ME2wMlIxPjd\|IN88US=>	M3fZcnNCVkeHUh?=
GOTO	NU\je4dtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7TTWM2OD1yLkKwO\|Mh\|ryP	NU\LW3VXW0GQR1XS
EW-3	MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2O0XWlEPTB;MD6yNVcyQCEQvF2=	MXfTRW5ITVJ?
KY821	NFfscnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPwdpVLUUN3ME2wMlIzODR3IN88US=>	MnPJV2FPT0WU
CTB-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnu4TWM2OD1yLkKyNlI5KM7:TR?=	M{\jPHNCVkeHUh?=
TALL-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXf5PFVTUUN3ME2wMlIzQTJzIN88US=>	NWPzfVBzW0GQR1XS
NCI-H209	MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMkK5OlIh\|ryP	NUSwPXdOW0GQR1XS
IST-MES1	NF;xVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwMkO1NUDPxE1?	MlrIV2FPT0WU
DMS-114	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXHTWM2OD1yLkKzPVk{KM7:TR?=	M{O3ZnNCVkeHUh?=
SNU-C2B	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXS1VpFJUUN3ME2wMlI1OzF4IN88US=>	M2nHOHNCVkeHUh?=
DG-75	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnmxTWM2OD1yLkK2NVk2KM7:TR?=	NWrP[GJxW0GQR1XS
D-336MG	Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fHVWlEPTB;MD6yOlU2PyEQvF2=	MWPTRW5ITVJ?
KMOE-2	NF[xZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrXeoJpUUN3ME2wMlI4PTN6IN88US=>	MX;TRW5ITVJ?
NB1	NUDzbWptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnyd2tWUUN3ME2wMlI4QTJ4IN88US=>	M1Hw[3NCVkeHUh?=
RH-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMke5PFkh\|ryP	Ml;OV2FPT0WU
TE-1	Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMki0O\|kh\|ryP	MmLtV2FPT0WU
RPMI-6666	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\CeWxKSzVyPUCuNlg5PCEQvF2=	NVfQNWQyW0GQR1XS
TE-9	NF\ifXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHiOG9WUUN3ME2wMlI5QTh3IN88US=>	M3nUOnNCVkeHUh?=
BT-474	M4H4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2GyT2lEPTB;MD6yPVM{PCEQvF2=	NEnSeYxUSU6JRWK=
COLO-668	NVjUZVYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMkm0Nlkh\|ryP	NXHvSnFSW0GQR1XS
NCI-H1581	MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXCRZpSUUN3ME2wMlI6Pjh7IN88US=>	NIPmPZdUSU6JRWK=
MN-60	NWCyV29iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnhcJRKSzVyPUCuNlk6ODVizszN	M1rWSnNCVkeHUh?=
L-540	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwM{CwPFEh\|ryP	MVzTRW5ITVJ?
MOLT-13	NEfyRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37P[mlEPTB;MD6zNFE5OyEQvF2=	M2fiPXNCVkeHUh?=
NCI-SNU-16	NULIXFY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwM{CyNFUh\|ryP	MUjTRW5ITVJ?
NCI-H64	NV3Sc\|dKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwM{CzN\|Eh\|ryP	MUDTRW5ITVJ?
CP66-MEL	NI\SbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnJTWM2OD1yLkOxOFE2KM7:TR?=	NXvUNFVrW0GQR1XS
NB69	M{\iNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLBN\|VKSzVyPUCuN\|IyQDhizszN	MWLTRW5ITVJ?
NCI-H2196	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwM{OwN\|Yh\|ryP	NE\WRmhUSU6JRWK=
MHH-CALL-2	NVL5UmptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;rflFtUUN3ME2wMlM{PDZ6IN88US=>	MX\TRW5ITVJ?
HCC2157	NG\4PWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXuxRYhEUUN3ME2wMlM{QTV2IN88US=>	NVy0Z5JrW0GQR1XS
LS-1034	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{npXmlEPTB;MD6zOlM5QCEQvF2=	MVPTRW5ITVJ?
BOKU	NIXaOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTnfnNFUUN3ME2wMlM4OTl7IN88US=>	MYTTRW5ITVJ?
GDM-1	NIjPWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPoPGFQUUN3ME2wMlM4OjN2IN88US=>	MlzaV2FPT0WU
TGW	M{HXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrXeHIxUUN3ME2wMlM4PDV\|IN88US=>	NWS2NIU5W0GQR1XS
SNU-C1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nr[2lEPTB;MD6zPFIyPSEQvF2=	M3fnc3NCVkeHUh?=
LS-513	M2jWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwM{mwO\|Eh\|ryP	MlXhV2FPT0WU
NOMO-1	NXXXfFRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlv3TWM2OD1yLkO5PVcyKM7:TR?=	NUHTTFM4W0GQR1XS
MS-1	MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PvVGlEPTB;MD60NFE4PyEQvF2=	M4XobXNCVkeHUh?=
EKVX	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn:zTWM2OD1yLkS0OFYyKM7:TR?=	NV7sUXFjW0GQR1XS
SK-MEL-2	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXiw[GI4UUN3ME2wMlQ3PCEQvF2=	NVnWOpRZW0GQR1XS
HCC1187	NF35U\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXZSVVKSzVyPUCuOFY4PjhizszN	MV\TRW5ITVJ?
HCC2218	Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwNEeyNlch\|ryP	NETsWGtUSU6JRWK=
NCI-H187	M1m2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGf6WWdKSzVyPUCuOFc5PCEQvF2=	NWXjdnFqW0GQR1XS
DB	NFr4bmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7PUWVQUUN3ME2wMlUxODV3IN88US=>	Mor6V2FPT0WU
NCI-H69	NFnL[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fJdmlEPTB;MD61NFI1PyEQvF2=	MnXpV2FPT0WU
NCI-H1694	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;MTWM2OD1yLkWwOlk4KM7:TR?=	M{H6b3NCVkeHUh?=
CA46	NYLM[JFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwNUC5NVch\|ryP	NXTrPI5CW0GQR1XS
EHEB	NUDvUpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwNUGxPVMh\|ryP	MmPoV2FPT0WU
NCCIT	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXTT4NKSzVyPUCuOVQ{OjFizszN	MY\TRW5ITVJ?
NCI-H720	MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rtdWlEPTB;MD61OFk3OiEQvF2=	NF22W2dUSU6JRWK=
LU-134-A	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\PcWJJUUN3ME2wMlU2Ojl4IN88US=>	MWLTRW5ITVJ?
MC-CAR	NWCxSGs6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVroTWFIUUN3ME2wMlU2PDNzIN88US=>	M1nqRXNCVkeHUh?=
NEC8	NF;GcnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwNU[xO\|Ih\|ryP	NInnWI1USU6JRWK=
NCI-H524	M{PPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYH5[GNiUUN3ME2wMlU5PzR6IN88US=>	MkLNV2FPT0WU
NCI-H1963	NUDFcm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjvTWM2OD1yLk[yOVgh\|ryP	NXj5TJdsW0GQR1XS
SU-DHL-1	MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Ptd2lEPTB;MD62OFUzPiEQvF2=	MX;TRW5ITVJ?
NCI-H1522	NHLLeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXK3dpBmUUN3ME2wMlY1QDh\|IN88US=>	NELnXodUSU6JRWK=
NCI-H1155	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInmNpRKSzVyPUCuOlU{PSEQvF2=	M33scnNCVkeHUh?=
D-263MG	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;EU2ZVUUN3ME2wMlY3OTBzIN88US=>	NISyPZRUSU6JRWK=
TE-6	NYX6[YRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\KR4hKSzVyPUCuOlgyODRizszN	MmnOV2FPT0WU
NCI-H1417	NF3GT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzKUI5MUUN3ME2wMlY6PzFzIN88US=>	M{[2[HNCVkeHUh?=
NCI-H510A	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwN{eyN\|Yh\|ryP	M4fUT3NCVkeHUh?=
KARPAS-45	NETndlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPxZXNtUUN3ME2wMlc5OjN3IN88US=>	NUKzNI1tW0GQR1XS
IST-SL1	MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzPTWM2OD1yLki1PFI2KM7:TR?=	NICydoVUSU6JRWK=
COLO-824	MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M16wc2lEPTB;MD64O\|g{PSEQvF2=	NWnvSG83W0GQR1XS
NCI-H526	M4PNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfMTHc6UUN3ME2wMlkxQTV6IN88US=>	MUnTRW5ITVJ?
NCI-H719	NWr4TZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33Fc2lEPTB;MD65OlY2PyEQvF2=	MoHDV2FPT0WU
SF539	MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\zNWtKSzVyPUCuPVg{QTZizszN	MXTTRW5ITVJ?
NKM-1	M13HOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPUZ3NKSzVyPUCuPVg3PjNizszN	MXfTRW5ITVJ?
A253	NYK2WnA4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIK0O29KSzVyPUCuPVg5QDVizszN	NWnwVYtIW0GQR1XS
TE-441-T	NWDwblNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVWzPGhjUUN3ME2xMlA1OzVizszN	MXHTRW5ITVJ?
COR-L88	M4G4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTFwMUGzOVQh\|ryP	MlPNV2FPT0WU
CPC-N	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvvTWM2OD1zLkG1PFg5KM7:TR?=	NFfiXohUSU6JRWK=
NCI-H2107	NGPiVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrvTWM2OD1zLkG3NlYyKM7:TR?=	M{W5RnNCVkeHUh?=
ECC4	MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTFwMUi2PVMh\|ryP	MkHqV2FPT0WU
NCI-H2141	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTFwMUmyPVkh\|ryP	MUjTRW5ITVJ?
NCI-H1770	NV7DV5loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPFZXBKSzVyPUGuN\|I6OjhizszN	NH\5Z4ZUSU6JRWK=
NCI-SNU-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTFwM{OwOEDPxE1?	MUXTRW5ITVJ?
LU-165	NUj6UZBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnVTWM2OD1zLkS1OFY4KM7:TR?=	M2XBcHNCVkeHUh?=
Raji	M4TkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1H2W2lEPTB;MT60O\|I2QSEQvF2=	M3fLTXNCVkeHUh?=
EW-24	M4TBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoG3TWM2OD1zLkW0OlE6KM7:TR?=	NXvuU\|huW0GQR1XS
KP-N-RT-BM-1	MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XWTWlEPTB;MT61OlU2OSEQvF2=	NGrTeVRUSU6JRWK=
SK-MEL-1	NYT4dGJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLORY9KSzVyPUGuOlQ5PzdizszN	NIrKPVBUSU6JRWK=
SCLC-21H	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELIcHdKSzVyPUGuOlY3PTFizszN	NFPie4xUSU6JRWK=
SIMA	NXrNUWx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\idY81UUN3ME2xMlY5OjN\|IN88US=>	NXLGOpI6W0GQR1XS
NCI-H1304	M16yN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTFwN{C3OlUh\|ryP	MnnlV2FPT0WU
REH	NUW4elV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTFwN{GwO\|gh\|ryP	MVTTRW5ITVJ?
KP-N-YS	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTFwOUO1OVEh\|ryP	MWHTRW5ITVJ?
DMS-153	M4[2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknjTWM2OD1zLkm3OVkh\|ryP	NYL0WoZKW0GQR1XS
NB10	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\5ZmlEPTB;Mj6yNFg4QCEQvF2=	NUnieZFrW0GQR1XS
NCI-H345	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHWTWM2OD1{Lk[xPVA2KM7:TR?=	Mo\zV2FPT0WU
SK-N-FI	M3P6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHm[HJKSzVyPUKuO\|U{QDFizszN	MnfRV2FPT0WU
NCI-H1092	NFzHXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPwTWM2OD1{Lkm1N\|k1KM7:TR?=	M2rIVnNCVkeHUh?=
KM-H2	NGi4dFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\kR446UUN3ME2zMlY2Ozl4IN88US=>	MWLTRW5ITVJ?
KG-1	NXnSdoRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnPTWM2OD1\|LkexOlg5KM7:TR?=	NVLofYFmW0GQR1XS
D-283MED	M1PQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jsU2lEPTB;Mz63OVg4KM7:TR?=	NX3Kfmg{W0GQR1XS
LU-65	NEfuWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nDcmlEPTB;ND6xNVQ5PSEQvF2=	NH23R4JUSU6JRWK=
MSTO-211H	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\Dd2lEPTB;ND6xPFg6QCEQvF2=	NXXyWYxCW0GQR1XS
NCI-H2081	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTRwMkmxO\|Qh\|ryP	NXXKdXNoW0GQR1XS
D-247MG	NUnoWWRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLFdGFKSzVyPUSuOFMyQTFizszN	M{HWenNCVkeHUh?=
P31-FUJ	NIm3[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIK2TVRKSzVyPUSuOFUxOTlizszN	NWO1T4NFW0GQR1XS
DMS-79	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfWTWM2OD12LkmzNVg{KM7:TR?=	NFKy[4FUSU6JRWK=
KASUMI-1	M2P2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TCOWlEPTB;ND65O\|UxQSEQvF2=	NFuyRlRUSU6JRWK=
JVM-3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTVwMkWwNVQh\|ryP	MWPTRW5ITVJ?
LAN-6	M{jaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjHTWM2OD13LkWxO\|M3KM7:TR?=	MX;TRW5ITVJ?
DJM-1	MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mny3TWM2OD13LkW2NFI6KM7:TR?=	MVzTRW5ITVJ?
JVM-2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HqO2lEPTB;NT62O\|A6OiEQvF2=	NEjHPYRUSU6JRWK=
U-87-MG	MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{D5XWlEPTB;NT64PVk3PCEQvF2=	NVHE[WVQW0GQR1XS
SHP-77	NHrNPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXsTWM2OD13Lkm0PVI5KM7:TR?=	M{C4TnNCVkeHUh?=
RPMI-8866	NHzRSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTZwMkewNVMh\|ryP	NGDRfpZUSU6JRWK=
ES7	M1vVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nL[mlEPTB;Nj6zPVkzPCEQvF2=	NVP6ZZUzW0GQR1XS
WSU-NHL	M2rqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rQbmlEPTB;Nj61NVYxQSEQvF2=	MkDQV2FPT0WU
CAS-1	M3Huemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUT2e4VuUUN3ME23MlA6PzR7IN88US=>	MX3TRW5ITVJ?
MHH-NB-11	MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRThwMkOxOVIh\|ryP	M33IT3NCVkeHUh?=
ES5	MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mor2TWM2OD17LkWyNlg3KM7:TR?=	M{e3XXNCVkeHUh?=
HDLM-2	M1rDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTlwOUW5NFIh\|ryP	NVTzRXFEW0GQR1XS
NCI-H2171	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHZTnNKSzVyPUGwMlU6OjdizszN	M2DoTHNCVkeHUh?=
LNCaP-Clone-FGC	M2Gy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17Td2lEPTB;MUGuN\|cyQCEQvF2=	MoryV2FPT0WU
NCI-H1395	MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWruSGxlUUN3ME2xNk4zPjl7IN88US=>	NFXLbHRUSU6JRWK=
NCI-H1436	NVi2NYZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXUV3FUUUN3ME2xN{4{OTl3IN88US=>	M1j6fXNCVkeHUh?=
RCC10RGB	M{XpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjYcpRKSzVyPUGzMlMzOjFizszN	NH73bZRUSU6JRWK=
SW684	NXvseHI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHrdFZHUUN3ME2xN{46Pzl5IN88US=>	MYHTRW5ITVJ?
NCI-H1650	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\KXmlEPTB;MUWuNFQ1PyEQvF2=	MXPTRW5ITVJ?
EW-13	M1u4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvhU5NRUUN3ME2xOU4zODJzIN88US=>	MnzZV2FPT0WU
EC-GI-10	NGmxN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrrV3E2UUN3ME2xOU45PjR2IN88US=>	NH7xTXpUSU6JRWK=
CHP-126	NFzETGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnH3TWM2OD1zNz6xPVE5KM7:TR?=	M3jJRnNCVkeHUh?=
NCI-H226	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLP[YEzUUN3ME2xPE4xPDB\|IN88US=>	M1TjfXNCVkeHUh?=
NCI-H1838	NHe1d49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTJyLkG4OFgh\|ryP	NIPyZmRUSU6JRWK=
EW-11	MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPUT5ZKSzVyPUK0MlI4OThizszN	M1vOcHNCVkeHUh?=
EB2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYL2cWZLUUN3ME2zNU42OzF6IN88US=>	NHnzU2lUSU6JRWK=
D-502MG	NHXXVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Ox[2lEPTB;NEOuPVIzQSEQvF2=	NWDRO4lZW0GQR1XS
U-698-M	MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTR6Lki2O\|Eh\|ryP	M4jLN3NCVkeHUh?=
ES3	NWHjVpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVr5PJIzUUN3ME20PU4{QDl\|IN88US=>	Ml\BV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	+ Expand Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: U87MG xenograft model Formulation: Torin1 powder is first dissolved at 25 mg/mL in 100% N-methyl-2-pyrrolidone and subsequently diluted 1:4 with sterile 50% PEG400 to a final concentration of 5 mg/mL Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

+ Expand

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 20% NMP+50% PEG 400 For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1